Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-11-07, 11:16:32 | version 1.33.00
kontinenz aktuell November/201410 Originalarbeit Reference List (1) Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impair- ment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 February 25; 332 (7539): 455–9. (2) Chew ML, Mulsant BH, Pollock BG. Serum anticholi- nergic activity and cognition in patients with moderate- to-severe dementia. Am J Geriatr Psychiatry 2005 June; 13 (6): 535–8. (3) Mach JR, Jr., Dysken MW, Kuskowski M, Richelson E, Holden L, Jilk KM. Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geriatr Soc 1995 May; 43 (5): 491–5. (4) Plaschke K, Hill H, Engelhardt R, Thomas C, von HR, Scholz M et al. EEG changes and serum anticholiner- gic activity measured in patients with delirium in the in- tensive care unit. Anaesthesia 2007 December; 62 (12): 1217–23. (5) Nebes RD, Pollock BG, Halligan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor per- formance in elderly persons. J Gerontol A Biol Sci Med Sci 2007 January; 62(1): 83–5. (6) Thomas C, Hestermann U, Kopitz J, Plaschke K, Os- ter P, Driessen M et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. BMC Neurosci 2008; 9: 86. (7) Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA et al. Anticholinergic acti- vity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008 July;56(7):1333–41. (8) Welz-Barth A, Wiedemann A, Wohltmann D, and Füsgen I. Tabu-Erkrankung Harninkontinenz – auch in der urologischen Praxis? 2001. Report No.: Urologe B 3 (2001). (9) Chancellor M, Boone T. Anticholinergics for over- active bladder therapy: central nervous system effects. CNS Neurosci Ther 2012 February;18(2):167–74. (10) Gulsun M, Pinar M, Sabanci U. Psychotic disorder induced by oxybutynin: Presentation of two cases. Clin Drug Investig 2006;26(10):603–6. (11) Pagoria D, O’Connor RC, Guralnick ML. Antimus- carinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011 October;12(5):351–7. (12) Womack KB, Heilman KM. Tolterodine and memo- ry: dry but forgetful. Arch Neurol 2003 May; 60 (5): 771–3. (13) Matsuo H, Matsui A, Nasu R, Takanaga H, Inoue N, Hattori F et al. Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodyna- mic study in mice. Pharm Res 2000 May;17 (5): 565–71. (14) Diefenbach K, Jaeger K, Wollny A, Penzel T, Fiet- ze I, Roots I. Effect of tolterodine on sleep structure mo- dulated by CYP2D6 genotype. Sleep Med 2008 July; 9 (5): 579–82. (15) Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I. Effects on sleep of anticholiner- gics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int 2005 Febru- ary;95(3):346–9. (16) Hunter KF, Voaklander D, Hsu ZY, Moore KN. Lo- wer urinary tract symptoms and falls risk among older women receiving home support: a prospective cohort study. BMC Geriatr 2013; 13:46. (17) Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency and related clini- cal factors. Age Ageing 1981 Novem- ber;10(4):264–70. (18) Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol 1989 July; 44 (4): M112-M117. (19) Gillespie WJ, Gillespie LD, Handoll HH, Madhok R. The Cochrane Musculoskeletal Injuries Group. Acta Orthop Scand Suppl 2002 October; 73 (305): 15–9. (20) Coster A, Haberkamp M, Allolio B. [Incidence of femoral neck fractures in the German Federal Republic in comparison to other countries]. Soz Praventivmed 1994; 39 (5): 287–92. (21) Wolinsky FD, Bentler SE, Liu L, Obrizan M, Cook EA, Wright KB et al. Recent hospitalization and the risk of hip fracture among older Americans. J Gerontol A Biol Sci Med Sci 2009 February; 64 (2): 249–55. (22) Wolinsky FD, Fitzgerald JF. The risk of hip fracture among noninstitutionalized older adults. J Gerontol 1994 July; 49 (4): S165-S175. (23) Wolinsky FD, Johnson RJ, Fitzgerald JF. Falling, he- alth status, and the use of health services by older adults. A prospective study. Med Care 1992 July; 30 (7): 587–97. (24) Moore DS, Ellis R, Kosma M, Fabre JM, McCarter KS, Wood RH. Comparison of the validity of four fall-re- lated psychological measures in a community-based falls risk screening. Res Q Exerc Sport 2011 Septem- ber; 82 (3): 545–54. (25) Delbaere K, Crombez G, Vanderstraeten G, Wil- lems T, Cambier D. Fear-related avoidance of activities, falls and physical frailty. A prospective community-ba- sed cohort study. Age Ageing 2004 July; 33 (4): 368–73. (26) Delbaere K, Crombez G, Van Den Noortgate N, Willems T, Cambier D. The risk of being fearful or fear- less of falls in older people: an empirical validation. Disabil Rehabil 2006 June 30; 28 (12): 751–6. (27) Gorska M. [Diabetes mellitus in the elderly]. Przegl Lek 2002; 59 (4–5): 201–3. (28) Runge M. [Falls of the elderly. Fate or disease?]. MMW Fortschr Med 2008 September 11; 150 (36–37): 49–50. (29) Runge M, Hunter G. Determinants of musculoskele- tal frailty and the risk of falls in old age. J Musculoskelet Neuronal Interact 2006 April; 6 (2): 167–73. (30) Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Mus- culoskelet Neuronal Interact 2005 June; 5 (2): 127–34. (31) Robinson M, Rowett D, Leverton A, Mabbott V. Changes in utilisation of anticholinergic drugs after ini- tiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf 2009 August; 18 (8): 659–64. (32) Hori K, Konishi K, Watanabe K, Uchida H, Tsuboi T, Moriyasu M et al. Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer’s disease. Neuropsychobiology 2011; 63 (3): 147–53. (33) Tune LE. Anticholinergic effects of medication in el- derly patients. J Clin Psychiatry 2001; 62 Suppl 21: 11–4. (34) Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000 April; 5 (2): 149–53. (35) Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor over- activity: a double-blind, placebo-controlled, randomi- zed study. Br J Clin Pharmacol 2006 April; 61 (4): 456–63. (36) Abrams P, Blaivas JG, Stanton SL, Andersen JT. The standardisation of terminology of lower urinary tract function. The International Continence Society Commit- tee on Standardisation of Terminology. Scand J Urol Nephrol Suppl 1988; 114: 5–19. (37) Wiedemann A. Solifenacin, Darifenacin, Oxybu- tynin TTS und Duloxetin: die neuen Inkontinenzmedika- mente. 2004. Report No.: Eur J Geriatrics 6 (2004):. (38) Folstein MF, Folstein SE, McHugh PR. „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 November; 12 (3): 189–98. (39) Ihl R, Frolich L, Dierks T, Martin EM, Maurer K. Dif- ferential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res 1992 November; 44 (2): 93–106. (40) Ihl R, Grass-Kapanke B, Lahrem P, Brinkmeyer J, Fi- scher S, Gaab N et al. [Development and validation of a test for early diagnosis of dementia with differentiati- on from depression (TFDD)]. Fortschr Neurol Psychiatr 2000 September; 68 (9): 413–22. denen verstärkt nicht-medikamentö- se Therapieformen beziehungswei- se Substanzen jenseits der Anticho- linergika zur Anwendung kommen sollten. Auch könnte der longitudi- nale Vergleich des wiederholten MMSE oder TFDD Veränderungen unter der Therapie mit anticholiner- gen Substanzen detektieren. Im Hinblick auf die große sozial- medizinische und gesundheitsöko- nomische Dimension der Sturznei- gung mit ihren Folgen wie Operati- on bei Verletzungen oder Fraktu- ren, Gelenkersatz und Heimein- weisung ist die Forderung nahelie- gend, die kognitiven Veränderun- gen vor Beginn einer anticholiner- gen Therapie auch in der Praxis systematisch zu erfassen und dies auch im Gesundheitssystem abzu- bilden. Sowohl der MMSE- als auch der TFDD-Test erscheinen hierfür im Setting einer urologi- schen Praxis unter Routinebedin- gungen geeignet. Interessenkonflikt: Der korrespondierende Autor gibt an, dass kein Interessenkonflikt be- steht. Korrespondenzanschrift: Priv.–Doz. Dr. Andreas Wiedemann Urologische Abteilung Evangelisches Krankenhaus im Diakoniewerk Ruhr gGmbH Lehrstuhl für Geriatrie der Universität Witten Pferdebachstraße 27–43 58455 Witten E-Mail: awiedemann@diakonie-ruhr.de